Arcutis Biotherapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

• Arcutis Biotherapeutics Inc ARQT.OQ reported a quarterly adjusted loss of 33 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -73 cents. The mean expectation of seven analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -46 cents to -36 cents per share.

• Revenue rose 17.4% to $44.76 million from a year ago; analysts expected $37.62 million.

• Arcutis Biotherapeutics Inc's reported EPS for the quarter was a loss of 33 cents​.

• The company reported a quarterly loss of $41.54 million.

• Arcutis Biotherapeutics Inc shares had held steady so far this quarter and gained 187.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 9.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is 19.00

This summary was machine generated from LSEG data November 6 at 11:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)